Many medical device companies assume that once technical documentation is complete, testing has been finalized, and the device performs as intended, regulatory timelines become relatively predictable. Yet effective regulatory strategy for medical devices typically requires organizations to look beyond submission readiness alone.
Increasingly, that assumption is being tested.
Across Europe and other major markets, regulatory timelines are being influenced by factors that extend well beyond the readiness of the device itself. Evolving guidance, changing expectations for clinical evidence, growing emphasis on post-market data, and increasing scrutiny of benefit-risk justifications are reshaping how innovative technologies move through the regulatory process.
The result is a reality that many regulatory leaders know well: a device can be technically ready, a submission can be well prepared, and yet timelines may still be influenced by factors that were difficult to anticipate when the project began.
For many medical device organizations, regulatory planning has traditionally been built around a straightforward assumption: if development milestones are achieved, technical documentation is complete, and submission packages are well prepared, market access timelines should remain largely predictable. Organizations that have already built regulatory strategy into earlier development stages tend to feel this shift less acutely, precisely because they were not relying on that assumption in the first place.
For the rest of the market, that assumption is becoming increasingly difficult to defend.
Across Europe and other major markets, regulatory outcomes are now influenced by a broader set of variables that extend beyond submission quality alone. Evolving regulatory expectations, changing interpretations of clinical evidence requirements, increased emphasis on post-market performance data, and heightened scrutiny of benefit-risk assessments are introducing new layers of uncertainty into regulatory planning.
As a result, regulatory strategy has become a business-critical function that directly influences portfolio prioritization, investment decisions, commercialization timelines, and long-term market access success.
Regulators are simultaneously responding to two powerful forces: the need to maintain robust standards of safety and performance, and the growing demand for faster patient access to innovation. New pathways, guidance documents, and evidence frameworks are emerging as regulators attempt to balance these priorities without compromising confidence in the technologies reaching the market.
Understanding this shift remains essential for companies that want to protect timelines, allocate resources effectively, and bring innovations to patients without unnecessary delays.
Why are Medical Device Regulatory timelines becoming less predictable?
Short answer: Medical device regulatory timelines are becoming less predictable because regulatory expectations continue to evolve. Clinical evidence requirements, post-market obligations, stakeholder involvement, and new regulatory initiatives all influence timelines in ways that extend beyond the readiness of the device itself.
For a significant part of the industry, regulatory approval has functioned as a relatively linear process: once development activities were completed and documentation prepared, the primary challenge was execution. Some organizations, particularly those already managing complex or innovative portfolios, have long treated regulatory strategy as a continuous discipline rather than a final step. What has changed is that this more dynamic approach is no longer optional for the rest of the market.
Regulatory authorities, notified bodies, expert panels, and industry stakeholders are continuously adapting to emerging technologies, evolving healthcare needs, and new approaches to evidence generation. This evolution is particularly visible in Europe, where implementation experience under the Medical Device Regulation (MDR) continues to shape how requirements are interpreted and applied in practice.
Recent proposals associated with MDR 2.0 further illustrate this trend. Rather than fundamentally changing the objectives of the regulatory framework, the proposed reforms seek to simplify regulatory processes, improve efficiency, support innovation, and enhance predictability while maintaining high standards of safety and performance.
As discussed by the Johner Institute in its analysis of the European Commission‘s MDR 2.0 proposal, many of the planned revisions focus on reducing regulatory burden while preserving the core objectives of the current framework. The direction of these discussions signals that regulatory frameworks are becoming increasingly responsive to both technological advancement and real-world implementation challenges.
For regulatory leaders, predictability increasingly depends not only on understanding the written requirements, but also on anticipating the broader direction of regulatory thinking and policy development.
Several factors contribute to this ongoing complexity:
- Evolving guidance and interpretation of existing requirements
- Increasing expectations for clinical evidence and benefit-risk justification
- Greater focus on post-market surveillance and PMCF activities
- Resource constraints across parts of the regulatory ecosystem
- New mechanisms designed to accelerate innovation while maintaining safety standards
None of these developments are inherently negative. In fact, many are intended to improve patient access to safe and effective technologies.
However, together they create an environment where timelines are influenced by a broader range of variables than ever before, for organizations still building this discipline and for those already accustomed to it alike.
These factors also help explain why medical device regulatory delays can occur even when development programs appear well planned and technically mature.
Similar concerns can also be observed in discussions around FDA approval delays for medical devices, reinforcing the fact that timeline uncertainty is not limited to a single market.
The shift from compliance reviews to benefit-risk conversations
One of the most significant changes in recent years has been the growing emphasis on clinical value.
Regulatory discussions increasingly focus not only on whether requirements have been met, but also on broader questions such as:
- What clinical problem does this device solve?
- How does it compare to existing alternatives?
- What evidence supports the expected clinical benefit?
- How much uncertainty remains?
- How will that uncertainty be addressed after market access?
For many organizations, these conversations begin long before a submission is filed.
Clinical evidence strategies, PMCF planning, literature approaches, and benefit-risk frameworks remain critical components of regulatory success and are becoming even more prominent. Decisions made early in development can have significant implications later in the review process.
This is particularly relevant for innovative technologies, where novelty often creates both opportunity and uncertainty.
The more innovative a technology is, the more important it becomes to demonstrate not only that it works, but also why the available evidence supports its expected clinical impact.
What does the new EU Breakthrough Device Pathway tell us about Regulatory Direction?
A recent example of this evolution can be seen in the upcoming EU Breakthrough Device pathway.
During a recent industry webinar discussing the initiative, regulators highlighted a growing recognition that Europe must continue supporting innovation while maintaining robust evidence standards.
As Donal O’Connor, Clinical Manager at the Irish Competent Authority and co-chair of the MDCG task force on breakthrough devices, explained:
“There was a call from all stakeholders that we needed to do a little bit more to promote innovation in Europe.”
The proposed framework introduces a structured pathway for devices that demonstrate both a high degree of novelty and the potential for significant positive clinical impact.
Interestingly, the framework does not limit novelty to entirely new technologies.
During the webinar, examples discussed included existing technologies being applied in ways that were not previously possible in clinical practice, such as enabling less invasive procedures or allowing earlier diagnosis and intervention. This broader interpretation reflects an important reality: meaningful innovation does not always come from inventing something entirely new. It can also emerge from applying existing technologies in ways that significantly improve patient outcomes or clinical workflows.
What is particularly noteworthy is what the initiative does not do.
As O’Connor emphasized:
“The intent is not to reduce requirements or to reduce the quality of clinical data that’s expected.”
The initiative instead reflects a broader effort to help innovative technologies move through the regulatory process while maintaining confidence in safety, performance, and clinical benefit.
A different approach to evidence generation
The introduction of the EU Breakthrough Device pathway offers a useful lens into how regulatory thinking is evolving.
At its core, the initiative acknowledges a challenge that regulators, manufacturers, and healthcare systems increasingly face: some of the most promising technologies do not fit neatly into traditional evidence-generation models.
Rather than lowering expectations, the proposed pathway seeks to create mechanisms that allow innovation to move forward while maintaining confidence in safety, performance, and clinical benefit.
This is reflected in several aspects of the proposed framework, including greater emphasis on early scientific advice, structured clinical development strategies, and well-defined post-market evidence generation plans.
One of the most interesting themes emerging from the discussion is the increased emphasis placed on how post-market evidence generation is planned and integrated into the overall evidence strategy. Post-market activities have long been a core component of the regulatory framework; however, the Breakthrough Device pathway brings greater attention to their role in supporting earlier access to innovative technologies.
The framework acknowledges that innovative technologies may involve higher levels of uncertainty at earlier stages, provided there is a clearly defined, methodologically robust plan for continuing evidence generation after market access. This shifts expectations upstream. Post-market strategies are no longer viewed solely as downstream regulatory commitments, but as critical elements that must be carefully designed before market entry, with clear objectives, endpoints, and data generation approaches.
As a result, the balance between pre-market and post-market activities evolves, without lowering expectations for safety, clinical performance, or evidence quality. Instead, there is a growing expectation that evidence generation will be planned as a continuous lifecycle activity, where pre-market and post-market data are aligned to collectively support regulatory, clinical, and market access objectives.
Innovation without lowering evidence expectations
The underlying message is significant.
Regulators are not signaling a reduction in evidence expectations. They are signalling a willingness to consider different approaches to evidence generation when the potential clinical impact justifies it.
For regulatory leaders, this distinction matters.
The conversation is increasingly shifting from “How much evidence do we need?” to “How should evidence be generated across the product lifecycle?”
Why are more stakeholders influencing regulatory timelines?
Another factor influencing predictability is the increasing number of stakeholders involved in certain regulatory pathways.
The proposed Breakthrough Device framework introduces a more prominent role for expert panels, particularly in providing scientific advice and supporting designation decisions. In parallel, notified bodies continue to evaluate conformity assessment requirements and clinical evidence expectations.
While these mechanisms are intended to support innovation, they also reflect a broader trend: regulatory decision-making is becoming increasingly collaborative.
For manufacturers, this means that regulatory success depends not only on preparing strong documentation, but also on anticipating questions from multiple perspectives, aligning evidence strategies early, and engaging the right stakeholders at the right time.
As regulatory ecosystems become more interconnected, predictability is increasingly influenced by the quality of those interactions.
Organizations that proactively seek scientific input, challenge assumptions early, and build evidence strategies around likely stakeholder expectations are often better positioned to avoid surprises later in the process.
Why predictability depends more on strategy than ever before
As the regulatory environment becomes more sophisticated, predictability increasingly depends on preparation rather than execution alone. A strong regulatory strategy for medical devices helps organizations anticipate challenges before they become timeline risks.
Companies that consistently navigate complex regulatory pathways successfully tend to focus on several areas early in development.
Evidence planning
Clinical evidence strategies should be developed alongside product development, not after it.
Questions around endpoints, comparators, PMCF activities, and benefit-risk justification become significantly more difficult to address late in the process.
Regulatory pathway planning
The most efficient pathway is not always the most obvious one.
Market priorities, classification considerations, available guidance, and emerging regulatory initiatives can all influence the optimal strategy.
Early identification of uncertainty
Every innovative technology contains elements of uncertainty.
Organizations that identify these areas early are often better positioned to generate the evidence needed to support future regulatory discussions.
Post-Market readiness
Increasingly, regulators expect manufacturers to demonstrate not only what they know today, but also how they will continue generating evidence after market access.
A well-designed PMCF strategy is becoming an essential component of regulatory planning rather than a post-approval exercise.
Questions Regulatory Leaders should be asking today
As regulatory expectations continue to evolve, leadership teams should regularly evaluate whether their current assumptions remain valid.
Some useful questions include:
- Are we planning based on today’s expectations or yesterday’s assumptions?
- Does our clinical evidence strategy adequately support our intended claims?
- Have we clearly articulated the clinical benefit our device is expected to provide?
- Are we prepared to justify both novelty and clinical impact?
- Have we identified potential bottlenecks before entering formal review?
- Is our PMCF strategy aligned with the level of innovation in our technology?
- Are we leveraging opportunities for early scientific dialogue when appropriate?
These questions may not eliminate uncertainty, but they can significantly improve preparedness.
What should medical device companies do next?
For regulatory leaders, the most practical response is not to wait for greater certainty.
It is to strengthen the areas that remain within their control.
This includes periodically reassessing evidence strategies, reviewing PMCF readiness, validating market access assumptions, and seeking scientific input early when uncertainty is high.
As regulatory frameworks continue to evolve, organizations that proactively challenge their own assumptions are often better positioned to adapt without disrupting development or commercialization plans.
Conclusion
The upcoming EU Breakthrough Device pathway illustrates a broader shift in regulatory thinking.
Regulators are actively exploring ways to support innovation while maintaining confidence in the evidence used to demonstrate safety, performance, and clinical benefit. The discussion is no longer limited to whether a device meets regulatory requirements. Increasingly, it focuses on how uncertainty is identified, justified, monitored, and reduced throughout the product lifecycle.
Recent MDR 2.0 proposals reinforce this direction. Measures aimed at improving predictability, supporting breakthrough and orphan devices, increasing flexibility around evidence generation, and reducing unnecessary regulatory burden suggest a growing recognition that regulatory systems must evolve alongside technological innovation and healthcare needs.
As highlighted in the Johner Institute’s analysis of the European Commission’s proposed MDR 2.0 revisions, these reforms are intended to simplify implementation while preserving the core objectives of patient safety and regulatory oversight. While the long-term impact of these reforms remains to be seen, they signal an important shift toward more adaptive regulatory frameworks.
For manufacturers, this has important implications. Regulatory strategy for medical devices can no longer be viewed as a late-stage activity centered on submission preparation. Decisions related to clinical evidence, PMCF strategy, market prioritization, and stakeholder engagement increasingly influence the predictability of regulatory timelines long before a dossier reaches review.
In our view, one of the biggest risks for medical device companies today is approaching regulatory strategy with assumptions that were valid five years ago, and this risk applies unevenly: organizations that have already modernized their approach are far less exposed than those still operating on outdated assumptions. The regulatory environment continues to evolve, and organizations that periodically reassess their evidence strategies, regulatory pathways, and market access plans are often better positioned to maintain momentum when expectations change.
The organizations most likely to succeed will not be those that simply react to regulatory change, but those that recognize emerging regulatory direction early and incorporate it into strategic planning. A number of organizations are already operating this way; for them, the shift described here is validation rather than a warning.
Predictability has become less about controlling every variable and more about identifying uncertainty early enough to make informed decisions before it becomes a delay.